Genetics of Women With Lobular Carcinoma in Situ of the Breast


RATIONALE: Gathering information about genetic changes in patients with lobular carcinoma in situ of the breast may help doctors learn more about the disease and find better methods of treatment. PURPOSE: This clinical trial is studying the genetics of women with lobular carcinoma in situ of the breast.

Full Title of Study: “GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope”

Study Type

  • Study Type: Observational

Detailed Description

OBJECTIVES: Primary – Identify inherited variation that predisposes women to develop lobular carcinoma in situ (LCIS) of the breast. – Identify the frequency of these variants and determine the effect they have on tumor risk. – Determine how worthwhile it would be to test for these variants in the clinical setting so that those at higher risk could be identified, counseled, and screened. Secondary – Analysis of genetic changes within LCIS with the aim of identifying cases of LCIS which may progress to invasive cancer. OUTLINE: Patients and control participants undergo blood collection. DNA is extracted from blood samples and used to genotype at selected polymorphisms, compare allele frequencies (used to associate alleles with disease) using a genome-wide single nucleotide polymorphism (SNP) screen. Archival tumor samples (if available) from patients are used for DNA-, RNA-, or protein-based analyses. All participants complete a questionnaire about family history, a brief medical history, and provide epidemiological data to a genetic counselor. Participants identified to be at risk for known hereditary predisposition to cancer will be referred to a clinical genetics service. Individual results of this study are not disclosed to participants. Peer Reviewed and Funded or Endorsed by Cancer Research UK. PROJECTED ACCRUAL: A total of 2,000 participants (1,000 patients and 1,000 matched controls) will be accrued for this study.


  • Genetic: gene expression analysis
  • Genetic: molecular diagnostic method
  • Genetic: polymorphism analysis
  • Genetic: protein expression analysis
  • Other: medical chart review
  • Other: questionnaire administration

Clinical Trial Outcome Measures

Primary Measures

  • Inherited variation predisposing development of lobular carcinoma in situ (LCIS) of the breast in women
  • Frequency and effect of variants on tumor risk
  • Clinical setting variant test value in identifying, counseling and screening those women at higher risk

Secondary Measures

  • LCIS genetic changes which may progress to invasive cancer

Participating in This Clinical Trial


  • Meets 1 of the following criteria: – Current or prior diagnosis of lobular carcinoma in situ (LCIS) of the breast, including any of the following cases: – Pure LCIS – LCIS with subsequent development of invasive breast cancer of any morphological subtype – LCIS presenting as an incidental finding together with invasive breast cancer of any morphological subtype – Control participant matched for age and ethnicity to each LCIS patient – Not affected by LCIS – No history of ductal carcinoma in situ of the breast – No breast cancer – No relative (up to 2nd degree) who has been affected by breast cancer – Male or female PATIENT CHARACTERISTICS: – Not specified PRIOR CONCURRENT THERAPY: – Not specified
  • Gender Eligibility: Female

    Minimum Age: N/A

    Maximum Age: 60 Years

    Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

    Investigator Details

    • Lead Sponsor
      • National Cancer Research Network
    • Overall Official(s)
      • Elinor Sawyer, MD, Study Chair, London Research Institute
      • Rebecca Roylance, MD, , Barts and the London School of Medicine and Dentistry

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.